Trial | NCT01324934  Report issue

Title

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids
Prospective, Randomized, Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of Immunosuppression Following a Heart-beating Cadaveric Renal Transplantation Based on the Use of Rabbit Anti-T-lymphocyte Serum, Tacrolimus and Mycophenolate, Free of Concomitant Corticosteroids From the Start of Immunosuppression

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    40
The main objective of the study is the assessment of the overall graft rejection rate (acute, chronic and subclinical) between a treatment with ATG-Fresenius administered in addition to standard treatment consisting of CellCept® or Myfortic®/TAC and without corticosteroids and a treatment consisting of CellCept® or Myfortic®/TAC and corticosteroids during the first year after renal transplantation.
Study Started
Oct 31
2006
Primary Completion
Jan 31
2011
Study Completion
Jan 31
2011
Last Update
May 01
2015
Estimate

Drug ATG-Fresenius S

Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory. (In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids).

Study Group Active Comparator

immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic

Control Group No Intervention

immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.

Criteria 

Inclusion Criteria

Signed and dated informed consent form,
End-stage renal disease,
Candidates for a first transplantation,
Re-transplant patients are eligible if a graft loss after transplantation was NOT due to immunological reasons,
Availability of a heart-beating cadaveric donor up to 70 years of age with a cold ischemia time shorter than 36 hours,
Male or female patients between 18 to 75 years of age inclusive,
Patients able to comply with all study related requirements,
Patients able to receive oral medication,
Women of childbearing age with a safe contraceptive method throughout the study.

Exclusion Criteria

Women who are pregnant or breast feeding,
Known Human Immunodeficiency Virus,
Hepatitis B Virus or Hepatitis C Virus infection,
Severe actual viral, bacterial or fungal infection not adequately controlled,
Patients with anamnestically known hypersensitivity to rabbit immunoglobulin antibodies or positive rabbit immunoglobulin skin test or known allergies to any component of the immunosuppressive drugs per protocol,
Patients at high immunological risk defined as current PRA > 25% or historical PRA > 50%,
Patients receiving pre-transplant immunosuppressive treatment, including corticosteroids,
Patients with current or history of malignancies (exception basal cell carcinoma or squamous cell carcinoma in remission),
Patients with previous transplantation except 1st graft loss due to surgical complications,
Patients receiving combined transplantation,
Patients with major organ dysfunctions,
Serious psychiatric or psychological disorders,
Pre-transplant thrombocytopenia: < 50,000 thrombocytes/µl, Pre-transplant leukopenia: < 2,000 leukocytes/µl,
Unable or unwilling to comply fully with the protocol,
Participation in another study of an investigational medicinal product concurrently or within the last 30 days.
No Results Posted